KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2025)

Recursion Pharmaceuticals' Return on Capital Employed history spans 5 years, with the latest figure at 0.5% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 3.0% year-over-year to 0.5%; the TTM value through Dec 2025 reached 0.5%, up 3.0%, while the annual FY2025 figure was 0.49%, 6.0% up from the prior year.
  • Return on Capital Employed reached 0.5% in Q4 2025 per RXRX's latest filing, up from 0.61% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.23% in Q3 2021 to a low of 0.71% in Q1 2024.
  • Average Return on Capital Employed over 5 years is 0.48%, with a median of 0.48% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: decreased -25bps in 2024, then increased 24bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.31% in 2021, then crashed by -42bps to 0.44% in 2022, then crashed by -44bps to 0.64% in 2023, then increased by 17bps to 0.53% in 2024, then rose by 6bps to 0.5% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Return on Capital Employed are 0.5% (Q4 2025), 0.61% (Q3 2025), and 0.57% (Q2 2025).